Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

David Richter

Rheumatology Akron, OH Medical Doctor

NPI 1821094954 CMS profile 36774

471 N Cleveland Massillon Rd, Akron, OH 44333

Open in the dashboard

General payments

$4,616

303 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, David Richter of Akron, OH is reported in the CMS Open Payments database as having received $4,616 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $125 1
2020 General $1,132 68
2019 General $3,359 234

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Richter
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to David Richter were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year David Richter Rheumatology median Middle half National median
2019 $3,359 $744 $153–$2,687 $163
2020 $1,132 $462 $98–$2,027 $114
2021 $125 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Amgen Inc. $765 34 payments
  2. Pfizer Inc. $703 65 payments
  3. AbbVie, Inc. $486 31 payments
  4. Janssen Biotech, Inc. $366 31 payments
  5. Genentech USA, Inc. $305 16 payments
  6. Novartis Pharmaceuticals Corporation $256 20 payments
  7. GlaxoSmithKline, LLC. $255 18 payments
  8. Lilly USA, LLC $249 16 payments
  9. UCB, Inc. $208 12 payments
  10. Mallinckrodt Enterprises LLC $202 9 payments
  11. Other $821 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $4,601 302 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2021
  1. XELJANZ $627 47 payments
  2. EVENITY $398 13 payments
  3. HUMIRA $392 22 payments
  4. Prolia $386 24 payments
  5. SIMPONI ARIA $366 31 payments
  6. Actemra $305 16 payments
  7. COSENTYX $256 20 payments
  8. BENLYSTA $255 18 payments
  9. TALTZ $249 16 payments
  10. Rituxan $223 15 payments
  11. Other $2,128 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record